medigraphic.com
SPANISH

Acta Médica Grupo Ángeles

Órgano Oficial del Hospital Ángeles Health System
  • Contents
  • View Archive
  • Information
    • General Information        
    • Directory
  • Publish
    • Instructions for authors        
    • Manuscript submission
    • Policies
    • Names and affiliations of the Editorial Board
  • About us
    • Data sharing policy
    • Stated aims and scope
  • medigraphic.com
    • Home
    • Journals index            
    • Register / Login
  • Mi perfil

2026, Number 3

<< Back Next >>

Acta Med 2026; 24 (3)

Analysis of antimicrobial resistance in bacterial infections at the Central Hospital of the State of Chihuahua

Jáuregui BRI, Molina CG, Pérez RMD, Nieto DJ
Full text How to cite this article 10.35366/123138

DOI

DOI: 10.35366/123138
URL: https://dx.doi.org/10.35366/123138

Language: Spanish
References: 22
Page: 207-214
PDF size: 688.31 Kb.


Key words:

targeted therapy, antimicrobial resistance, extended resistance, multidrug resistance, healthcareassociated infection.

ABSTRACT

Introduction: antimicrobial resistance is a major challenge in the management of infections associated with health care. Objective: determine the patterns of antimicrobial resistance in bacterial infections at the Central Hospital of the State of Chihuahua. Material and methods: a non-experimental, descriptive, analytical study was conducted, as well as the study design is observational, cross-sectional and retrospective. 328 bacterial isolates were collected from the last two years from patients hospitalized at the Central Hospital of the State of Chihuahua. Results: it was generated through standard microbiological identification methods and antimicrobial sensitivity testing. Identifying high rates for third-generation cephalosporins, carbapenems and aminoglycosides. The most affected areas are the ICU and surgical areas. The most prevalent HAIs were VAP. Conclusions: the conclusions include the design of hospital guidelines adapted to the actual epidemiological evidence of the hospital center under study.


REFERENCES

  1. Aiesh BM, Nazzal MA, Abdelhaq AI, Abutaha SA, Zyoud SH,Sabateen A. Impact of an antibiotic stewardship program on antibioticutilization, bacterial susceptibilities, and cost of antibiotics. Sci Rep. 2023; 13 (1): 5040. doi:10.1038/s41598-023-32329-6.

  2. Aslam B, Wang W, Arshad MI, Khurshid M, Muzammil S, Rasool MHet al. Antibiotic resistance: a rundown of a global crisis. Infect DrugResist. 2018; 11: 1645-1658. doi: 10.2147/IDR.S173867.

  3. Ayukekbong JA, Ntemgwa M, Atabe AN. The threat of antimicrobialresistance in developing countries: causes and control strategies.Antimicrob Resist Infect Control. 2017; 6: 47. doi: 10.1186/s13756-017-0208-x.

  4. Camacho Silvas LA. Resistencia bacteriana, una crisis actual. Rev EspSalud Publica. 2023; 97: e202302013.

  5. Secretaría de Salud. Guía para la vigilancia por laboratorio de laresistencia a los antimicrobianos [Internet]. Ciudad de México:Secretaría de Salud; 2022. Disponible en: https://www.gob.mx/cms/uploads/attachment/file/943601/Gu_a_para_la_Vigilancia_por_Laboratorio_de_la_Resistencia_a_los_Antimicrobianos.pdf

  6. Hernández A, Yagüe G, García Vázquez E, Simón M, Moreno ParradoL, Canteras M et al. Infecciones nosocomiales por Pseudomonasaeruginosa multirresistente incluido carbapenémicos: factorespredictivos y pronósticos. Estudio prospectivo 2016-2017. Rev EspQuimioter. 2018; 31 (2): 123-130.

  7. Jiménez Pearson MA, Galas M, Corso A, Hormazábal JC, DuarteValderrama C, Salgado Marcano N et al. Consenso latinoamericanopara definir, categorizar y notificar patógenos multirresistentes, conresistencia extendida o panresistentes. Rev Panam Salud Publica.2019; 43: e65. doi: 10.26633/RPSP.2019.65.

  8. Lepe JA, Martínez-Martínez L. Puesta al día en medicina intensiva:infecciones graves por gramnegativos multirresistentes. Mecanismosde resistencia en bacterias gramnegativas. Med Intensiva. 2022; 46(1): 1-9. doi: 10.1016/j.medin.2022.02.004.

  9. Shallcross LJ, Howard SJ, Fowler T, Davies SC. Tackling the threat ofantimicrobial resistance: from policy to sustainable action. Philos TransR Soc Lond B Biol Sci. 2015; 370 (1670): 20140082. doi: 10.1098/rstb.2014.0082.

  10. Organización Mundial de la Salud. Lista de patógenos bacterianosprioritarios de la OMS, 2024: patógenos bacterianos de importanciapara la salud pública para guiar la investigación, el desarrollo y lasestrategias para prevenir y controlar la resistencia a los antimicrobianos[Internet]. Ginebra: OMS; 2024. Disponible en: https://iris.who.int/bitstream/handle/10665/376776/9789240093461-eng.pdf?sequence=1

  11. EClinicalMedicine. Antimicrobial resistance: a top ten global publichealth threat. EClinicalMedicine. 2021; 41: 101221. doi: 10.1016/j.eclinm.2021.101221.

  12. Global burden of bacterial antimicrobial resistance in 2019: asystematic analysis. Lancet. 2021; 399 (10325): 629-655. doi:10.1016/S0140-6736(21)02724-0.

  13. Muteeb G, Rehman MT, Shahwan M, Aatif M. Origin of antibioticsand antibiotic resistance, and their impacts on drug development:a narrative review. Pharmacol. 2023; 16 (11): 1615. doi: 10.3390/ph16111615.

  14. Pérez-Torres D, Tamayo-Lomas LM, Domínguez-Gil González M,Almendros-Muñoz R, Sacristán-Salgado MA, González-González Eet al. Programa de optimización del uso de antimicrobianos en unServicio de Medicina Intensiva: análisis retrospectivo observacionalde los resultados 15 meses después de su implementación. Rev EspQuimioter. 2023; 36 (5): 477-485. doi: 10.37201/req/142.2022.

  15. Osorio G, Fresco L, Monclús E, Carbó M, Ortega M. Adecuacióndel uso de antibióticos de “Categoría Especial” en el Servicio deUrgencias de un hospital de tercer nivel. Rev Esp Quimioter. 2020;33 (1): 24-31. doi: 10.37201/req/066.2019.

  16. Evans L, Rhodes A, Alhazzani W, Antonelli M, Coopersmith CM,French C et al. Surviving sepsis campaign: international guidelines formanagement of sepsis and septic shock 2021. Intensive Care Med.2021; 47 (11): 1181-1247. doi: 10.1007/s00134-021-06506-y.

  17. Smith J, Johnson L, Martinez R. Antimicrobial stewardship programsand the reduction of antimicrobial resistance: A review of currentevidence. J Antimicrob Chemother. 2022; 77 (5): 1123-1130.

  18. Brown A, Davis M, Wilson T. Guidelines for the treatment ofantimicrobial-resistant infections in adults. Clin Infect Dis. 2021; 73(8): e262-e278.

  19. Wang X, Zhang Y, Liu T. Surveillance and reporting of antimicrobialresistance: a global perspective. J Glob Health. 2021; 11 (2): 02003.

  20. Moreno LI, Garza-González E. Active surveillance of antimicrobialresistance and carbapenemase-encoding genes according to sites ofcare and age groups in Mexico: results from the INVIFAR Network.Pathogens. 2023; 12 (9): 1144. doi: 10.3390/pathogens12091144.

  21. Consejo de Salubridad General. Acuerdo por el que se declarala obligatoriedad de la Estrategia Nacional de Acción contra laResistencia a los Antimicrobianos [Internet]. Diario Oficial de laFederación; 5 de junio de 2018 [citado 24 de marzo de 2025].Disponible en: https://dof.gob.mx/nota_detalle.php?codigo=5525043&fecha=05/06/2018#gsc.tab=0

  22. Plan Universitario de Control de la Resistencia Antimicrobiana(PUCRA), Universidad Nacional Autónoma de México.Recomendaciones para el control de la resistencia antimicrobianaen México [Internet]. Ciudad de México: UNAM; 2019 [citado24 de marzo de 2025]. Disponible en: http://www.puis.unam.mx/ReportePUCRArecomendaciones.pdf




2020     |     www.medigraphic.com

Mi perfil

C?MO CITAR (Vancouver)

Acta Med. 2026;24